Please wait while the formulary information is being retrieved.
CIMDUO (lamivudine/tenofovir disoproxil fumarate)
- HIV infection
300 mg-300 mg tablet
- 1 tablet by oral route once daily
300 mg-300 mg tablet
- 1 tablet by oral route once daily
HIV infection
- 1 tablet by oral route once daily
- adefovir
- cidofovir
- Hepsera
- Vistide
Contraindicated
- None
Severe
Moderate
- Advil
- Advil Allergy Sinus
- Advil Allergy-congestion Rlf
- Advil Cold & Sinus
- Advil Congestion Relief
- Advil Liqui-gel
- Advil Migraine
- Advil Pm
- Advil Pm Liqui-gels
- Aleve
- Aleve Cold & Sinus
- Aleve Sinus & Headache
- Aleve-d Sinus & Cold
- Aleve-d Sinus & Headache
- All Day Pain Relief
- All Day Pain Relief Sinus & Co
- All Day Relief
- Anaprox
- Anaprox Ds
- Ansaid
- Arthrotec 50
- atazanavir
- Caldolor
- Cambia
- Cataflam
- Celebrex
- celecoxib
- Child Ibuprofen
- Children's Advil
- Children's Ibu-drops
- Children's Ibuprofen
- Children's Medi-profen
- Children's Motrin
- Children's Profen Ib
- chlorphen-phenyleph-ibuprofen
- chlorphen-pseudoeph-ibuprofen
- Cold & Sinus Pain Relief
- Cold-sinus Relief
- Daypro
- diclofenac epolamine
- diclofenac potassium
- diclofenac sodium
- diclofenac submicronized
- diclofenac-misoprostol
- didanosine
- Duexis
- Ec-naprosyn
- etodolac
- Feldene
- fenoprofen
- Flanax
- Flector
- flurbiprofen
- hydrocodone-ibuprofen
- I-prin
- Ibu-drops
- Ibudone
- ibuprofen
- Ibuprofen Cold
- Ibuprofen Cold-sinus(with Pse)
- Ibuprofen Ib
- Ibuprofen Jr Strength
- ibuprofen lysine (PF)
- Ibuprofen Pm
- ibuprofen-diphenhydramine
- ibuprofen-diphenhydramine HCl
- ibuprofen-famotidine
- ibuprofen-oxycodone
- ibuprofen-phenylephrine HCl
- Incivek
- Indocin
- indomethacin
- indomethacin sodium
- Infant's Ibuprofen
- Infant's Medi-profen
- Infant's Motrin
- Infants Ibu-drops
- Infants Profenib
- ketoprofen
- ketorolac
- Medi-profen
- Mediproxen
- mefenamic acid
- meloxicam
- Midol (naproxen)
- Mobic
- Motrin Ib
- Motrin Pm
- nabumetone
- Nalfon
- Naprelan Cr
- Naprosyn
- naproxen
- naproxen sodium
- naproxen-esomeprazole
- naproxen-pseudoephedrine
- Neoprofen (ibuprofen Lysn)(pf)
- oxaprozin
- Pennsaid
- piroxicam
- Ponstel
- Provil
- pseudoephedrine-ibuprofen
- Reprexain
- Reyataz
- Sinus & Cold-d
- Solaraze
- Sprix
- sulindac
- telaprevir
- tolmetin
- Vicoprofen
- Videx 2 Gram Pediatric
- Videx 4 Gram Pediatric
- Videx Ec
- Vimovo
- Voltaren-xr
- Wal-profen
- Wal-profen Cold-sinus
- Wal-proxen
- Zipsor
- Zorvolex
- Acute pancreatitis
- Chronic pancreatitis
- Lactating mother
- Lactic acidosis
Contraindicated
- Acute renal failure
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Fanconi syndrome
- Hypophosphatemia
- Osteomalacia
- Pathological fracture
Severe
Moderate
- Kidney disease with likely reduction in GFR
- Osteopenia
CIMDUO (lamivudine/tenofovir disoproxil fumarate)
- HIV infection
- Depression
- Elevated serum lipase
- Paresthesia
- Skin rash
- Acute abdominal pain
- Back pain
- Cough
- Diarrhea
- Dizziness
- Fatigue
- Fever
- Flatulence
- General weakness
- Headache disorder
- Infection of ear
- Insomnia
- Malaise
- Nausea
- Pain
- Peripheral neuropathy
- Pruritus of skin
- Sore throat
- Vomiting
More Frequent
Severe
Less Severe
- Hypercholesterolemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Neutropenic disorder
- Pneumonia
- Thrombocytopenic disorder
- Abdominal pain with cramps
- Anorexia
- Arthralgias
- Chest pain
- Chills
- Dizziness
- Dyspepsia
- Fatigue
- Insomnia
- Myalgias
- Pharyngitis
- Polyuria
- Proteinuria
- Rhinitis
- Sinusitis
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute renal failure
- Anaphylaxis
- Anemia
- Angioedema
- Dyspnea
- Fanconi syndrome
- Graves' disease
- Guillain-barre syndrome
- Hepatitis
- Hypokalemia
- Hypophosphatemia
- Interstitial nephritis
- Kidney disease with reduction in GFR
- Lactic acidosis
- Lymphadenopathy
- Nephrogenic diabetes insipidus
- Osteomalacia
- Pancreatitis
- Peripheral neuropathy
- Polymyositis
- Pure red cell aplasia
- Renal tubular necrosis
- Rhabdomyolysis
- Splenomegaly
- Steatosis of liver
Less Severe
- Alopecia
- Cramps
- General weakness
- Hyperglycemia
- Hyperhidrosis
- Hypertriglyceridemia
- Muscle weakness
- Myopathy
- Pruritus of skin
- Skin rash
- Stomatitis
- Urticaria
- Wheezing
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Lamivudine,tenofovir DF
TDF increases bone turnover with unknown impact on long-term bone health. Risk of pancreatitis from lamivudine. No safety and efficacy established with weight < 35 kg.
TDF increases bone turnover with unknown impact on long-term bone health. Risk of pancreatitis from lamivudine; risk highest in patients with prior antiretroviral nucleoside exposure and patients with other risk factors for pancreatitis.
- 1 Day – 8 Years
- TDF increases bone turnover with unknown impact on long-term bone health. Risk of pancreatitis from lamivudine. No safety and efficacy established with weight < 35 kg.
- TDF increases bone turnover with unknown impact on long-term bone health. Risk of pancreatitis from lamivudine; risk highest in patients with prior antiretroviral nucleoside exposure and patients with other risk factors for pancreatitis.
- 8 Years – 18 Years
- TDF increases bone turnover with unknown impact on long-term bone health. Risk of pancreatitis from lamivudine. No safety and efficacy established with weight < 35 kg.
- TDF increases bone turnover with unknown impact on long-term bone health. Risk of pancreatitis from lamivudine; risk highest in patients with prior antiretroviral nucleoside exposure and patients with other risk factors for pancreatitis.
Lamivudine
- Severity Level:
2
- Additional Notes: No fda cat;art preg registry data show no increased risk for major birth defects
Tenofovir
- Severity Level:
2
- Additional Notes: Available human data show no increased risk for major birth defects
Contraindicated
Lamivudine
Avoid breastfeeding in hiv positive women per cdc
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Excreted | Not known; no or inclusive data | Avoid breastfeeding in hiv positive women per cdc |
Precaution Exists
Tenofovir
Limited data suggest no known adverse effects in nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest no known adverse effects in nursing infant |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Tenofovir Disoproxil
Renal-Adjust dosing interval for CrCL<50mL/min. Fixed dose combinations containing tenofovir are not appropriate if dose adjustment is required. Musculoskeletal-Decreases in bone mineral density have been observed. Consider calcium and vitamin D3 supplementation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- If you have hepatitis B infection as well as HIV, your hepatitis symptoms may get worse or become very serious if you stop taking this medication. Talk with your doctor before stopping this medication. Your doctor will check your liver function tests for several months after you stop. Tell your doctor right away if you develop symptoms of worsening liver problems.
| HIV infection | |
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
| 0-9 | A-Z |
|---|---|
| B20 | Human immunodeficiency virus [HIv] disease |
| B97.35 | Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere |
| O98.7 | Human immunodeficiency virus [HIv] disease complicating pregnancy, childbirth and the puerperium |
| O98.71 | Human immunodeficiency virus [HIv] disease complicating pregnancy |
| O98.711 | Human immunodeficiency virus [HIv] disease complicating pregnancy, first trimester |
| O98.712 | Human immunodeficiency virus [HIv] disease complicating pregnancy, second trimester |
| O98.713 | Human immunodeficiency virus [HIv] disease complicating pregnancy, third trimester |
| O98.719 | Human immunodeficiency virus [HIv] disease complicating pregnancy, unspecified trimester |
| O98.72 | Human immunodeficiency virus [HIv] disease complicating childbirth |
| O98.73 | Human immunodeficiency virus [HIv] disease complicating the puerperium |
| Z21 | Asymptomatic human immunodeficiency virus [HIv] infection status |
Formulary Reference Tool